Tenaya Therapeutics financials
$0.5931+0.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $225.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $1.1M | $225.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$42.7M | -$20.1M | -$20.8M | -$20.9M | -$24.1M | -$27.5M | -$24.7M | -$26.7M | -$30.8M | -$33.8M | -$31.4M | -$30.9M |
| Net income | -$43.4M | -$19.3M | -$20.2M | -$20.3M | -$23.3M | -$26.9M | -$23.8M | -$25.6M | -$29.4M | -$32.2M | -$29.9M | -$29.1M |
| Net margin | −3909.3% | −8565.3% | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.20 | $-0.09 | $-0.11 | $-0.12 | $-0.14 | $-0.24 | $-0.28 | $-0.30 | $-0.34 | $-0.40 | $-0.40 | $-0.39 |
| EBITDA | -$19.2M | -$18.3M | -$18.9M | -$19.1M | -$22.0M | -$24.9M | -$22.6M | -$24.6M | -$28.7M | -$31.6M | -$29.3M | -$28.7M |
| Operating cash flow | -$3.6M | -$19.2M | -$13.9M | -$15.6M | -$15.6M | -$23.1M | -$18.4M | -$19.8M | -$23.6M | -$28.7M | -$21.9M | -$23.6M |
| Free cash flow | -$3.7M | -$19.2M | -$14.0M | -$15.6M | -$15.8M | -$23.5M | -$18.6M | -$20.0M | -$23.7M | -$29.2M | -$22.3M | -$23.6M |
| Diluted shares | 217.6M | 216.9M | 175.9M | 163.3M | 162.8M | 109.9M | 86.4M | 86.2M | 85.7M | 81.0M | 74.7M | 73.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $78.1M | $80.9M | $100.5M | $56.3M | $62.7M | $53.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $9.0M | $34.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $93.5M | $135.1M | $146.9M | $105.0M | $122.2M | $144.0M |
| Total liabilities | $24.1M | $28.9M | $23.7M | $22.1M | $22.3M | $24.6M |
| Shareholders' equity | $69.4M | $106.2M | $123.3M | $82.9M | $99.8M | $119.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology